+1-786-628-7980
Sign Up/Sign In 
TargEDys and Biocodex are partners since 2019, when Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became distributor of TargEDys’ leading PreciBiomic in France, and then in Portugal. Now the partnership extends with an exclusive marketing and distribution agreement signed to bring Symbiosys Satylia, a food supplement based on the next-generation probiotic Hafnia alvei HA4597 to Polish consumers.
Symbiosys Satylia is a precision probiotic supplement with a deeply characterized mechanism of action at the molecular level: it increases the feeling of fullness thanks to the ability of the probiotic protein ClpB to mimic the satiety hormone alpha-MSH. The efficacy was demonstrated in a clinical trial involving 230 overweight adults. It is a new, natural, safe, and effective solution to weight management and a multi-award winner – including Best Probiotic of the Year 2021 by the internationally-recognized NutraIngredients Awards.
Grégory Lambert, CEO of TargEDys:
“As pioneer in precision probiotics, we are pleased to expand our partnership with Biocodex, one of the trailblazers of probiotics, to Poland. We share the drive of a Microbiota Mission and the aim of improving quality of life and health status of consumers through breakthrough microbiome-based innovations and education.”
Nicolas Coudurier, CEO of Biocodex:
“Symbiosys Satylia definitely represents an innovative option to answer growing problems of weight management and thus improve health and well-being of women and men in Poland. With this launch, we are thrilled to complement our probiotic-based solutions already available in Poland and as historical partners of TargEDys, to reinforce our cooperation in Central Europe.”
About Biocodex – “Healthcare with passion and conviction”
Biocodex is an independent multinational pharmaceutical company built on high-standard science and manufacturing, with seven decades of proven success. Founded in 1953, Biocodex’s initial focus was gastroenterology featuring a unique probiotic Saccharomyces boulardii CNCM I-745®, the first probiotic drug of its kind that has a positive effect on the gut’s microflora.
More information on www.biocodex.com
About TargEDys® – “From Probiotics to PreciBiomics”
TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions for the control of appetite through microbiome interventions. The company is the fruit of 15 years of research on the microbiota conducted within academic laboratories. The team developed and started the commercialization of a first product based on the PreciBiomic, or precision probiotic strain Hafnia alvei HA4597™ which efficacy in weight and appetite has been clinically demonstrated. Targedys® develops a product portfolio focusing on overweight, undernutrition and mental health, all based on the concept of PreciBiomic strains backed by a molecular mechanism of action and in vivo studies.
More information on www.targedys.com
